🌸Protecting Women’s Health: The Role of ¹⁸F-FDG PET in Women’s Cancer Diagnosis and Management

2026-03-08

In modern oncology, molecular imaging has become an essential bridge between basic research and clinical medicine. Among these technologies, ¹⁸F-FDG PET imaging enables visualization of tumor metabolism and plays a crucial role in the early detection, staging, and treatment evaluation of women’s cancers such as breast cancer and ovarian cancer.

On International Women’s Day, it is particularly meaningful to reflect on how medical innovation continues to support the protection of women’s health worldwide.

Women’s cancers: a global health challenge

In recent decades, cancers affecting women—including breast cancer, ovarian cancer, and cervical cancer—have become major public health concerns.

Breast cancer is now one of the most frequently diagnosed cancers worldwide. Ovarian cancer, although less common, remains one of the most lethal gynecologic malignancies because early symptoms are often subtle and diagnosis frequently occurs at advanced stages.

Improving outcomes for these diseases depends heavily on early detection, accurate staging, and continuous monitoring of treatment response.

Among molecular imaging technologies, ¹⁸F-FDG PET imaging offers the ability to visualize tumor metabolism at the cellular level, providing valuable information that complements traditional anatomical imaging methods.

Understanding tumor metabolism: the Warburg effect

More than a century ago, scientists discovered that cancer cells often consume glucose at a significantly higher rate than normal cells. Even in the presence of sufficient oxygen, tumor cells tend to rely heavily on glycolysis for energy production. This phenomenon is widely known as the Warburg effect.

As a result of this altered metabolism, tumor tissues often exhibit increased glucose uptake compared to surrounding normal tissues. This metabolic characteristic provides a powerful biological target for modern molecular imaging techniques.

By visualizing metabolic activity rather than only structural changes, clinicians are able to gain deeper insight into tumor biology.

¹⁸F-FDG: a radiotracer that mimics glucose

The most widely used radiotracer for metabolic imaging in nuclear medicine is ¹⁸F-FDG (Fluorine-18 Fluorodeoxyglucose).

Because FDG closely resembles glucose in its molecular structure, it is transported into cells through glucose transporters. Once inside the cell, FDG is phosphorylated to FDG-6-phosphate. However, unlike normal glucose, it cannot continue through metabolic pathways and therefore becomes trapped within the cell.

Cancer cells, due to their elevated metabolic activity, accumulate greater amounts of FDG. This accumulation can be detected using PET imaging, allowing clinicians to visualize areas of abnormal metabolic activity.

When Fluorine-18 undergoes positron decay, it emits positrons that interact with electrons and generate pairs of gamma photons traveling in opposite directions. PET scanners detect these signals and reconstruct detailed images that reflect metabolic activity throughout the body.

This metabolic imaging approach enables physicians to identify abnormal cellular activity even before structural abnormalities become visible in conventional imaging modalities such as CT or MRI.

FDG PET in breast cancer evaluation

Breast cancer is a highly heterogeneous disease with different molecular subtypes exhibiting distinct biological behaviors, treatment responses, and prognoses.

FDG PET imaging provides important metabolic information about breast tumors.

Several metabolic parameters derived from PET imaging are commonly used in clinical evaluation:

SUVmax (Maximum Standardized Uptake Value)

This parameter reflects the highest level of FDG uptake within the tumor and is widely used to assess metabolic intensity.

MTV (Metabolic Tumor Volume)

MTV represents the volume of tumor tissue that exhibits significant metabolic activity.

TLG (Total Lesion Glycolysis)

TLG combines both tumor volume and metabolic activity to estimate the overall metabolic burden of the disease.

Together, these parameters provide clinicians with deeper insight into tumor aggressiveness, treatment response, and potential disease progression.

Clinical value of FDG PET in ovarian cancer

Ovarian cancer remains one of the most lethal malignancies of the female reproductive system. One major reason for this is that early symptoms are often non-specific, leading to delayed diagnosis in many patients.

In this context, FDG PET/CT imaging provides significant advantages. By combining anatomical imaging with metabolic information, PET/CT improves the detection of metastatic lesions and supports more accurate disease staging.

These insights support more personalized treatment planning and contribute to improved patient management.

The importance of reliable ¹⁸F production

The widespread clinical use of FDG PET imaging relies on the stable and continuous availability of the radionuclide Fluorine-18.

With a half-life of approximately 110 minutes, Fluorine-18 is ideally suited for PET imaging, providing high-quality images while allowing sufficient time for radiopharmaceutical preparation and clinical use.

In practice, ¹⁸F is produced using medical cyclotrons and subsequently synthesized into FDG radiopharmaceuticals for diagnostic imaging.

As the global demand for PET imaging continues to grow, reliable cyclotron systems and efficient isotope production capabilities are becoming increasingly important components of nuclear medicine infrastructure.

On this International Women’s Day, we recognize the critical role that⁸F-FDG and cyclotron systems play in advancing women’s health and improving cancer care worldwide.